deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02795182

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 With BGB-A317 in Subjects With B-Cell Lymphoid Malignancies

Sponsor: BeiGene

Conditions Leukemia Lymphoma
Interventions Tislelizumab Zanubrutinib
Updated 17 times since 2017 Last updated: Mar 16, 2022 Started: Jun 29, 2016 Primary completion: Dec 18, 2020 Completion: Dec 18, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Leukemia and Lymphoma, this trial is completed. The trial is conducted by BeiGene and has accumulated 17 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Dec 2017 · 11 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2019 · 13 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Sep 2021 — Sep 2022 [monthly]

    Completed PHASE1

  5. Apr 2021 — Sep 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 12 earlier versions

  1. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  4. Feb 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  6. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  7. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  8. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  9. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Jul 2019 [monthly]

    Recruiting PHASE1

  11. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  12. Jan 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeiGene
Data source: BeiGene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations